Se JUL kosour 1 2008
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
: REGULATORY AUTHORITY
Safe Medical Devices Act of 1990, 21 CFR 807.92
COMPANY NAME/CONTACT
Heather MacFalls
Reliant Technologies, Inc.
464 Ellis St.
Mountain View, CA 94043
650 605-2257
650 605-2057 fax
hmacfalls(@fraxel.com
NAME OF DEVICE
Trade Name: Fraxel re:pair™ (Fraxel II] SR) Laser System and
Accessories
Common Name: Laser Surgical Instrument
Regulation Number 878.4810
Product code: GEX
Device Panel: General Surgery/Restorative Devices
Device Classification: Class IT
LEGALLY MARKETED PREDICATE DEVICES
Name: Fraxel re:pair (Fraxel II] SR) Laser System and Accessories
510(k) #: K063038, K071051
Name: Lumenis UltraPulse Encore Carbon Dioxide Surgical Laser and Delivery
Device Accessories
510(k) #: K022060, K030147
DEVICE DESCRIPTION
The Fraxel re:pair Laser System consists of a CO2 laser source and three delivery
handpieces for resurfacing, incision and debulking procedures. Each handpiece attaches
to an articulating arm. Additional device accessories include interchangeable resurfacing
treatment tips, incisional handpiece spatulas, and debulking handpiece spatulas.

, 4“

[cof ty
INDICATION FOR USE STATEMENT
The Fraxel re:pair (Fraxel 11] SR) Laser System, including its resurfacing handpiece
delivery system, is intended for use in:
-Dermatological procedures requiring ablation (removal), resurfacing and coagulation of
soft tissue.
-Treatment of wrinkles, rhytides, furrows, fine lines;
-Pigmented lesions;
-Textural irregularities;
-Vascular dyschromia.
The Fraxel re:pair (Fraxel II] SR) Laser System, including its incisional and debulking
delivery systems, are intended for ablation (removal), for the reduction, treatment and/or
removal of:
- Actinic and seborrheic keratoses;
-Chelitis;
-Cutancous horns;
-Hemangiomas;
-Keloids;
-Nevi, including spider, epidermal and protruding;
-Rhinophyma;
-Syringomas;
-Warts;
-Laser incision and/or excision for the performance of upper and lower eyelid
blepharoplasty and vermilionectomy of the lip.
SUBSTANTIAL EQUIVALENCE COMPARISON
Indications for Use
Substantial equivalence for the Fraxel re:pair Laser System and Accessories is supported
by the predicate devices listed in this submission, which have identical or similar
indications for use statements and equivalent performance specifications.
Clinical Performance Data
Non-Significant Risk and Investigational Device Exemption studies to support the
clinical performance of the Fraxel re:pair Laser System and its resurfacing handpiece.
The substantial equivalence of the incisional and debulking handpieces supported the
determination of safety and effectiveness for the Fraxel re:pair Laser System and
Accessories. Unique device features do not introduce new issues of safety and
effectiveness.

Jeo P28 Uy

Technological Characteristics

Key technological characteristics for the resurfacing, incisional and debulking delivery

systems for the Fraxel re:pair Laser System, such as energy type and operating principle,

are equivalent to the Fraxel re:pair Laser System as described in submissions K063038

and K071051 and to the Lumenis Ultrapulse Encore Laser System as described in

K020660 and K030147.

CONCLUSION

Based on the design, materials, function, specifications and intended use, the Fraxel

re:pair Laser System and Accessories is substantially equivalent to the devices currently
: marketed under the Federal Food, Drug and Cosmetic Act. Safety and effectiveness are

reasonably assured, justifying 510(k) clearance.

s J DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
me Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
JUL -1 2008
Reliant Technologies, Inc.
Yo Ms. Heather MacFalis
Clinical and Regulatory Affairs
464 Ellis Street ‘
Mountain View, California 94043
Re: KO80915
Trade/Device Name: Fraxel re:pair (Fraxel II] SR) Laser System and accessories
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic
surgery and in dermatology
Regulatory Class: IT
Product Code: GEX
Dated: March 31, 2008
Received: April 02, 2008
Dear Ms. MacFalls:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class I] (Special Controls) or class II] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.

; Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies, You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 — Ms. Heather MacFalls
This letter will allow you to begin marketing your device as described in your Section $10(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance at
(240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification” (21CFR Part 807.97). For questions regarding postmarket surveillance,
please contact CDRH’s Office of Surveillance and Biometric’s (OSB’s) Division of Postmarket
Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events
(Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems
at (240) 276-3464. You may obtain other general information on your responsibilities under the
Act from the Division of Small Manufacturers, International and Consumer Assistance
at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address
hitp://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Director

Division of General, Restorative

and Neurological Devices
Office of Device Evaluation
, Center for Devices and
Radiological Health

Enclosure

indications for Use
~ a
@
510(k) Number (ifknown):; K OP? 71S
Device Name: Fraxel re:pair (Fraxel Ill SR) Laser System and accessories
Indications For Use:
The Fraxel re:pair (Fraxel Ill SR) Laser System, including its resurfacing handpiece delivery system, is
intended for use in:
-Dermatological procedures requiring ablation (removal), resurfacing and coagulation of soft tissue.
-Treatment of wrinkles, rhytides, furrows, fine lines;
-Pigmented lesions;
-Textural irregularities;
-Vascular dyschromia.
The Fraxel re:pair (Fraxel Ill SR) Laser System, including its incisional and debulking delivery systems,
are intended for ablation (removal), for the reduction, treatment and/or removal of:
~ Actinic and seborrheic keratoses;
-Chelitis;
-Cutaneous horns;
~Hemangiomas,
-Keloids:
-Nevi, including spider, epidermal and protruding;
-Rhinophyma;
-Syringomas;
-Warts;
-Laser incision and/or excision for the performance of upper and lower eyelid blepharoplasty and
vermilionectomy of the lip.
Prescription Use Xx AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) . (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE N ANOTHER PAGE IF
NEEDED)
f ce
Concurrence of CDRH, Office of BEIMBariation ODE 1 of 1
Divistor: a: ues rs Fstorate,
and Neurwiae: «Vet cea
_, Hot OVE
BAO(K) Nearer

